תוצאות חיפוש - Alba A. Brandes
- Showing 1 - 20 results of 77
- Go to Next Page
-
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
Recurrence Pattern After Temozolomide Concomitant With and Adjuvant to Radiotherapy in Newly Diagnosed Patients With Glioblastoma: Correlation With <i>MGMT</i> Promoter Methylation... מאת Alba A. Brandes, Alicia Tosoni, Enrico Franceschi, Guido Sotti, G. Frezza, Pietro Amistà, Luca Morandi, F. Spagnolli, Mario Ermani
יצא לאור 2009Artigo -
10
Second-Line Chemotherapy With Irinotecan Plus Carmustine in Glioblastoma Recurrent or Progressive After First-Line Temozolomide Chemotherapy: A Phase II Study of the Gruppo Italian... מאת Alba A. Brandes, Alicia Tosoni, Umberto Basso, Michele Reni, F. Valduga, S. Monfardini, Pietro Amistà, Linda Nicolardi, Guido Sotti, Mario Ermani
יצא לאור 2004Artigo -
11
-
12
-
13
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO) מאת Alba A. Brandes, A. Tosoni, Giovanni Cavallo, Roberta Bertorelle, V. Gioia, Enrico Franceschi, M Biscuola, V. Blatt, Lucio Crinò, Mario Ermani
יצא לאור 2006Artigo -
14
-
15
Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma מאת Salveena Schiffgens, Ludwig Wilkens, Alba A. Brandes, Tatiana Meier, Enrico Franceschi, Mario Ermani, Christian Hartmann, I. Erol Sandalcioglu, Claudia A. Dumitru
יצא לאור 2016Artigo -
16
A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro‐Oncologia מאת Alba A. Brandes, Giovanna Cavallo, Michele Reni, Alicia Tosoni, Linda Nicolardi, L. Scopece, Enrico Franceschi, Guido Sotti, Andrea Talacchi, S. Turazzi, Mario Ermani
יצא לאור 2005Artigo -
17
First-Line Chemotherapy With Cisplatin Plus Fractionated Temozolomide in Recurrent Glioblastoma Multiforme: A Phase II Study of the Gruppo Italiano Cooperativo di Neuro-Oncologia מאת Alba A. Brandes, Umberto Basso, Michele Reni, Francesca Vastola, Alicia Tosoni, Giovanna Cavallo, L. Scopece, Andrés J.M. Ferreri, Maria Grazia Panucci, S. Monfardini, Mario Ermani
יצא לאור 2004Artigo -
18
Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Ne... מאת Alba A. Brandes, A. Tosoni, Enrico Franceschi, V. Blatt, Armando Santoro, Marina Faedi, Pietro Amistà, Marina Gardiman, Roberto Labianca, C. Bianchini, Mario Ermani, Michele Reni
יצא לאור 2009Artigo -
19
Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO) מאת Enrico Franceschi, Giovanni Cavallo, Sara Lonardi, Elisabetta Magrini, A. Tosoni, Domenico Grosso, L. Scopece, V. Blatt, Benedetta Urbini, Andrea Pession, Giovanni Tallini, Lucio Crinò, Alba A. Brandes
יצא לאור 2007Artigo -
20
<i>MGMT</i> Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients מאת Alba A. Brandes, Enrico Franceschi, Alicia Tosoni, V. Blatt, Annalisa Pession, Giovanni Tallini, Roberta Bertorelle, Stefania Bartolini, Fabio Calbucci, Alvaro Andreoli, G. Frezza, Marco Leonardi, F. Spagnolli, Mario Ermani
יצא לאור 2008Artigo
כלי חיפוש:
נושאים קשורים
Medicine
Internal medicine
Oncology
Chemotherapy
Cancer research
Temozolomide
Radiation therapy
Surgery
Cancer
Glioma
Clinical trial
Astrocytoma
Biology
Glioblastoma
Clinical endpoint
Gene
Randomized controlled trial
Confidence interval
Cyclophosphamide
Progression-free survival
Lomustine
Phases of clinical research
Vincristine
Gastroenterology
Dacarbazine
Hazard ratio
Bevacizumab
Biochemistry
Oligodendroglioma
Pathology